Show simple item record

Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.

dc.contributor.authorBayman, Neil A
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorJain, Pooja
dc.contributor.authorLee, Lip W
dc.contributor.authorThatcher, Nick
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2009-04-01T23:20:46Z
dc.date.available2009-04-01T23:20:46Z
dc.date.issued2008-03
dc.identifier.citationManagement of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. 2008, 9 (2):92-101 Clin Lung Canceren
dc.identifier.issn1525-7304
dc.identifier.pmid18501095
dc.identifier.doi10.3816/CLC.2008.n.014
dc.identifier.urihttp://hdl.handle.net/10541/58717
dc.description.abstractLung cancer remains the most common cause of cancer deaths in the United Kingdom, and long-term survival from lung cancer has hardly improved over the past 30 years. The benefit of combined-modality therapy with chemotherapy and radiation therapy in improving survival for patients with inoperable non-small-cell lung cancer (NSCLC) was discovered over 10 years ago. In this comprehensive literature review, we discuss the current status of combined-modality therapy for unresectable stage III NSCLC. The efficacy and toxicity of different chemoradiation therapy regimens are presented. The potential role of novel and targeted therapies and radiation dose escalation is also considered. Finally, recommendations are made for the treatment of unresectable stage III NSCLC.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshClinical Trials as Topic
dc.subject.meshCombined Modality Therapy
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshRadiotherapy
dc.titleManagement of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Manchester, UK. neil.bayman@christie.nhs.uken
dc.identifier.journalClinical Lung Canceren
html.description.abstractLung cancer remains the most common cause of cancer deaths in the United Kingdom, and long-term survival from lung cancer has hardly improved over the past 30 years. The benefit of combined-modality therapy with chemotherapy and radiation therapy in improving survival for patients with inoperable non-small-cell lung cancer (NSCLC) was discovered over 10 years ago. In this comprehensive literature review, we discuss the current status of combined-modality therapy for unresectable stage III NSCLC. The efficacy and toxicity of different chemoradiation therapy regimens are presented. The potential role of novel and targeted therapies and radiation dose escalation is also considered. Finally, recommendations are made for the treatment of unresectable stage III NSCLC.


This item appears in the following Collection(s)

Show simple item record